Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3 | Zendy

Stefan Zeuzem | Zendy; Geoffrey Dusheiko | Zendy; Riina Salupere | Zendy; Alessandra Mangia | Zendy; Robert Flisiak | Zendy; Robert H. Hyland | Zendy; Ari Illeperuma | Zendy; Evguenia S. Svarovskaia | Zendy; Diana M. Brainard | Zendy; William T. Symonds | Zendy; G. Mani Subramanian | Zendy; John G. McHutchison | Zendy; Ola Weiland | Zendy; Hendrik W. Reesink | Zendy; Péter Ferenci | Zendy; Christophe Hézode | Zendy; Rafael Esteban | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

Author(s) -

Stefan Zeuzem,

Geoffrey Dusheiko,

Riina Salupere,

Alessandra Mangia,

Robert Flisiak,

Robert H. Hyland,

Ari Illeperuma,

Evguenia S. Svarovskaia,

Diana M. Brainard,

William T. Symonds,

G. Mani Subramanian,

John G. McHutchison,

Ola Weiland,

Hendrik W. Reesink,

Péter Ferenci,

Christophe Hézode,

Rafael Esteban

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1316145

Subject(s) - sofosbuvir , ribavirin , medicine , hepatitis c virus , genotype , gastroenterology , regimen , placebo , hepatitis c , cirrhosis , immunology , virus , pathology , biology , gene , biochemistry , alternative medicine

In clinical trials, treatment with a combination of the nucleotide polymerase inhibitor sofosbuvir and the antiviral drug ribavirin was associated with high response rates among patients with hepatitis C virus (HCV) genotype 2 infection, with lower response rates among patients with HCV genotype 3 infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research